The anterior vestibule of the nose is an important reservoir of Staphylococcus aureus, and dissemination of this organism by carriers is important in the perpetuation and spread of staphylococcal disease (3, 12, 36) . Staphylococci are responsible for more than 80% of the suppurative diseases found in medical practice (34) and are a major problem in newborn nurseries and neonatal intensive care units (11, 15) . Additionally, the emergence of methicillin-resistant strains of staphylococci (6, 14, 17, 22) and strains with multiple resistance patterns (9, 10, 13, 21, 26, 28) heightened the importance of finding methods to treat staphylococcal disease, the staphylococcal carrier state, and associated nosocomial outbreaks (8, 19) .
Bryan et al. (7) have reported that 70%o of hospitals continue to obtain cultures from personnel during staphylococcal disease outbreaks, and about 40% prescribe topical antibiotic ointment for personnel with positive cultures. Although two studies performed in the 1950s (24, 32) reported that bacitracin ointment may be effective in controlling the carrier state and recent reports recommend use of topical antibiotics (23, 27, 29) , there remains some question regarding the efficacy of bacitracin and other topical ointments (7, 19, 35) . Recent studies (7, 8, 19) have suggested a need for further prospective controlled trials on the efficacy of topical bacitracin ointment and the establishment of more definitive guidelines relative to its use (7) .
Several systemic antibiotic regimens also have been used to eradicate the staphylococcal carrier state (37, 38) . In most cases, only a temporary suppression was achieved, persisting for a very short time after therapy was stopped. In a retrospective study, Sande and Mandell (25) have shown that rifampin may have considerable efficacy in eradicating nasal staphylococci. Most strains of S. aureus are exquisitely sensitive to low concentrations of rifampin (40) . The drug penetrates well into nasopharyngeal secretions (16) , and spread of rifampin-resistant strains appears to be minimal (25 able to eliminate nasal carriage of S. aureus among 80% of a group of male medical students given rifampin with or without cloxacillin. Their study also demonstrated that treatment with rifampin was effective in the eradication of coagulase-positive staphylococci in most subjects for 12 weeks after treatment (33) .
The purpose of this study was to investigate the impact of systemic rifampin and topical bacitracin therapy, both alone and in combination, on nasal carriage of S. aureus among an occupationally diverse group of medical center personnel. We report the results of a randomized-controlled trial on persistent S. aureus nasal carriers. written informed consent. Each volunteer was randomly assigned to one of four groups. The three treatment groups were as follows: (i) 600 mg of rifampin taken once a day for 5 days, (ii) bacitracin ointment applied three times a day for 10 days, and (iii) a combination of both treatment regimens. The fourth group consisted of untreated controls. Fifty-nine subjects completed the study in full compliance with their assigned treatment regimens. There were no significant differences among the groups completing therapy based on age distribution, six ratio, or occupational distribution (Table 1). No adverse side effects were reported from any of the subjects during the study.
MATERIALS AND METHODS
Posttreatment nasal cultures from all groups were obtained 2 and. 4 weeks after completion of the 10-day course of bacitracin therapy. This corresponded to 21 and 35 days after completion of rifampin therapy because rifampin was taken for only 5 days. Culturing and identification were performed as previously described; all coagulase-positive isolates were shipped for phage typing.
MIC tests. Rifampin MICs were performed on all 132 isolates obtained from the 59 subjects who completed the study. Bacitracin MICs were performed on 53 randomly selected isolates. The MICs were performed by the agar dilution method (1); rifampin was prepared at doubling dilutions from 0.004 through 2.0 p.g/ml, and bacitracin was prepared at doubling dilutions from 0.0625, through 32 ,ug/ml. These were prepared in Mueller-Hinton agar and poured to a depth of 4 mm in 150-mnm plates. The plates were dried overnight and stored in the dark to avoid inactivation of the rifampin. After standardization of inoculum densities, each isolate was spotted onto the plates with 0.001-ml inoculating loop, and the plates were read after incubation at 35°C for 18 h.
Combination MICs were performed on 10 isolates; 5 were selected from pretreatment cultures and 5 were from posttreatment cultures. Bacitracin at levels of 0.5 and 1.0 ,ug/ml was combined with rifampin at doubling dilutions from 0.001 through 2.0 ,ug/ml. The bacitracin levels were selected to be just below the previously determined MICs for these strains. These combination studies were performed by the agar dilution method described above.
Phage (4) . RESULTS Table 2 shows the distribution of nasal S. aureus carriers among the three major categories of medical center personnel. Initial cultures showed that the medical and dental provider rates (36.1 and 26.1%, respectively) were significantly higher than the rate among administrative personnel (19.1%). However, when persistent carriage was calculated from 1-month follow-up cultures, there were no significant differences among the three groups. A significant reduction in carriers among dental providers (P < 0.02 versus medical providers) at the 1-month follow-up culture indicated that there was a high level of transient colonization among the dental providers.
Culture results from 59 subjects who completed antibiotic treatment are shown in Table 3 . Rifampin-treated subjects showed the highest reduction in carriage (79%) at the first posttreatment culture. A reduction of only 13% was observed among the bacitracin-treated group, which was virtually equal to that observed in the untreated group (control). Combination antibiotic therapy yielded a 42% reduction in carriers, which was less effective than rifampin therapy alone but more effective than bacitracin therapy. The highly significant reduction in carriers among rifampin-treated subjects (P < 0.001 versus control and bacitracin groups) was (Table 4) . The data analysis shown in Table 3 depicts only total elimination of S. aureus carriage. When elimination of specific typeable strains of S. aureus was also considered as a treatment success, the group which received comnbination therapy exhibited a significant reduction in carriage (data not shown). This reduction was significant at both the first (P < 0.05 versus bacitracin) and second (P < 0.05 versus control; P < 0.01 versus bacitracin) posttreatment cultures.
Agar dilution rifampin MICs were performed on 132 isolates from both pre-and posttreatment cultures in each of the four groups; all of the isolates were susceptible to less than 0.016 ,ug of rifampin per ml. A total of 53 randomly selected isolates were tested against bacitracin: 36 were sensitive to less than 2 ,ug/ml, and 17 were sensitive to less than 4 ,ug/ml. Multiple concentrations of bacitracin and rifampin were tested in combination, and the interaction was found to be indifferent because the effect was equal to or less than that of the most active drug in the combination (1) .
DISCUSSION
This study demonstrates that rifampin is an effective antibiotic for eradicating nasal carriage of S. aureus. A significant proportion of nasal carriers were free of S. aureus for more than 1 month after completing a 5-day course of rifampin therapy, and some subjects were negative when tested as much as a year later. Our results support previous observations of the carrier state during use of rifampin in antituberculous therapy (25) and also closely parallel results obtained in a similar study in which a 10-day course of rifampin was used to eliminate the carrier state (33) . Recent reports of nosocomial outbreaks caused by multiply antibiotic-resistant staphylococci have demonstrated that these strains are difficult to eliminate from the hospital environment (6, 14, 19, 22) . Although it has been shown that these resistant strains exhibit poor carrier colonizing potential (21, 22) , only a small number of colonized personnel are necessary to perpetuate an outbteak (17, 19) . Reporting on a large outbreak of multiply antibiotic-resistant S. aureus, Locksley et al. (19) have found that the outbreak was controlled only (2, 18, 20, 25, 39) . For this reason, in addition to the potential renal and hepatotoxic problems associated with use of rifampin, it is generally recommended that it be used to eradicate colonization only in high-risk situations, and then only in combination with an additional antistaphylococcal antibiotic (19, 20, 39) . Rifampin in combination with trimethoprim-sulfamethoxazole has been used successfully to eradicate the carrier state in patients colonized at both nasal and extranasal sites (31) . Evaluation of such combinations in patients with clinical problems resulting from the carrier state, such as recurrent furunculosis, is clearly warranted.
